Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapy product candidates for cancer, with its lead program ELI-002 7P aimed at mKRAS-driven tumors. The company does not yet have approved products or product revenue and is still centered on research, clinical development, and intellectual property protection.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead and pipeline therapeutic candidates designed to treat cancer through immune-based mechanisms.
Early-stage programs and discovery work intended to generate future clinical candidates.
AMP platform and related intellectual property used to support internal development and potential partnering.
Potential non-product revenue sources such as partnerships, licenses, or similar strategic deals.
Internal and outsourced R&D activities supporting clinical and preclinical advancement.
Customers
Elicio does not currently sell approved products, so its near-term counterparties are primarily clinical investigators, contract research organizations, manufacturers, and potential licensing partners rather than end-market patients. If its programs succeed, future customers would include oncology physicians, hospitals, and payors that adopt the approved therapies. The company’s commercial opportunity is therefore still dependent on regulatory success and on whether partners or healthcare systems see clinical and reimbursement value.
Investigators, CROs, and CMOs that execute trials, manufacture materials, and support regulatory development.
Biopharma companies that may license or collaborate on the AMP platform or pipeline assets.
Hospitals and oncology physicians that would prescribe the therapy if approved and clinically adopted.
Government and private payors that would determine coverage and reimbursement after approval.
Strategy
Elicio’s strategy is to advance ELI-002 7P into late-stage clinical trials, move preclinical programs into the clinic, and broaden its pipeline around its AMP platform. It also aims to protect its intellectual property, pursue regulatory approvals, and potentially supplement internal development through acquisitions or in-licensing. Because it has no approved products, execution is mainly about converting scientific assets into clinical and regulatory milestones while preserving cash runway.
The lead asset is the main value driver and the clearest path to clinical and regulatory validation.
A deeper pipeline reduces single-asset dependence and improves long-term partnering optionality.
Patent coverage is central to differentiation, partnering leverage, and eventual commercialization.
Geography
Elicio is headquartered in Boston, Massachusetts, and operates as a U.S.-based clinical-stage biotech company. It also has an Australian subsidiary established to support research credit qualification for studies conducted in Australia. The company’s disclosed risk profile highlights reliance on foreign and foreign-owned vendors for certain clinical and discovery activities, which creates supply-chain and regulatory exposure.
Risks
Elicio faces the classic risks of a clinical-stage biotech: it has no approved products, recurring losses, and a need for substantial additional capital, with management disclosing substantial doubt about going concern. Development, regulatory, manufacturing, and reimbursement outcomes are uncertain, and any delay or failure can materially impair value. The company also depends on patent protection and third-party vendors, including foreign suppliers, which adds IP, supply-chain, and regulatory risk.
- Financing and going concern riskImpact: CriticalLikelihood: High
The company has recurring operating losses and will need additional capital to fund development beyond its current runway.
Exposure - Clinical and regulatory failureImpact: HighLikelihood: High
Pipeline value depends on successful trial outcomes and FDA/foreign regulatory approvals, which are inherently uncertain.
Exposure: ELI-002 7P and preclinical oncology programs
- Intellectual property protectionImpact: HighLikelihood: Medium
The company’s competitive position relies on patents for the AMP platform and specific cancer programs.
Exposure - Third-party manufacturing and vendor dependenceImpact: MediumLikelihood: Medium
Clinical materials and services are outsourced, so vendor noncompliance or disruption can delay development.
Exposure - Reimbursement and commercialization uncertaintyImpact: MediumLikelihood: Medium
Even if approved, payor coverage and pricing pressure may limit adoption and economics.
Exposure: Future oncology commercialization in the U.S. and abroad
Accounting
Judgemental itemsClinical and outsourced development services are often billed after work is performed, requiring estimates at period-end.
Impact: Can shift operating expenses between quarters and affect comparability
Management states that recurring losses and capital needs create substantial doubt about continued operations.
Impact: Important for liquidity analysis and financing assumptions
As a development-stage public company, stock compensation is likely a meaningful non-cash expense.
Impact: Affects reported operating loss and share-based dilution analysis
Any future partnering revenue will depend on contract terms and performance obligations.
Impact: Could materially affect revenue recognition timing if deals are signed
Similar listed companies
Publicly listed companies with a comparable business focus.
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
Lexeo Therapeutics, Inc.
LXEO · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a U.S.-based clinical-stage biotechnology company developing gene therapy candidates for serious cardiovascular and neuromuscular diseases.
MAIA Biotechnology, Inc.
MAIA · Pharmaceutical Preparations
Last updated: 24/09/2026